Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1.
Heredia
A
A
Margolis
D
D
Oldach
D
D
Hazen
R
R
Le
N
N
Redfield
R
R
D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000494:pharmacology* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors; D009173:Mycophenolic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D007168:IMP Dehydrogenase; D009173:Mycophenolic Acid; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir